Schizophrenia Clinical Trial
Official title:
A Phase 3 Study to Assess the Long Term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831 in Subjects With Schizophrenia, Schizophreniform Disorder, or Bipolar I Disorder
Verified date | February 2024 |
Source | Alkermes, Inc. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This study will evaluate the long-term safety, tolerability, and durability of treatment effect of ALKS 3831 in subjects with schizophrenia, schizophreniform disorder, or bipolar I disorder
Status | Completed |
Enrollment | 524 |
Est. completion date | September 6, 2023 |
Est. primary completion date | September 6, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 16 Years to 70 Years |
Eligibility | Inclusion Criteria: - Willing and able to give informed consent/assent as per local requirements - Agrees to use an acceptable method of contraception during the study, and for 30 days after any study drug administration, unless surgically sterile or post-menopausal - Has the potential to benefit from the administration of ALKS 3831, in the opinion of the investigator - Subject met the eligibility criteria of the antecedent study at the time of enrollment in the antecedent study and completed the treatment period in one of the following antecedent studies within 7 days: ALK3831-A304, ALK3831-A306, or ALK3831-A307 - Additional criteria may apply Exclusion Criteria: - Has any finding that, in the view of the investigator or medical monitor, would compromise the safety of the subject or affect their ability to fulfill the protocol visit schedule or visit requirements - Has a positive drug screen for drugs of abuse at study entry - Currently pregnant or breastfeeding or is planning to become pregnant during the study or within 30 days of the last study drug administration - Additional criteria may apply |
Country | Name | City | State |
---|---|---|---|
Austria | Alkermes Investigational Site | Vienna | |
Bulgaria | Alkermes Investigational Site | Burgas | |
Bulgaria | Alkermes Investigational Site | Lovech | |
Bulgaria | Alkermes Investigational Site | Novi Iskar | |
Bulgaria | Alkermes Investigational Site | Plovdiv | |
Bulgaria | Alkermes Investigational Site | Sofia | |
Bulgaria | Alkermes Investigational Site | Tserova Koria | |
Bulgaria | Alkermes Investigational Site | Veliko Tarnovo | |
Bulgaria | Alkermes Investigational Site | Vratsa | |
Ireland | Alkermes Investigational Site | Galway | |
Israel | Alkermes Investigational Site | Jerusalem | |
Israel | Alkermes Investigational Site | Ramat Gan | |
Italy | Alkermes Investigational Site | Brescia | |
Italy | Alkermes Investigational Site | Napoli | |
Korea, Republic of | Alkermes Investigational Site | Busan | |
Poland | Alkermes Investigational Site | Poznan | |
Puerto Rico | Alkermes Investigational Site | San Juan | |
Russian Federation | Alkermes Investigational Site | Arkhangel'sk | |
Russian Federation | Alkermes Investigational Site | Moscow | |
Russian Federation | Alkermes Investigational Site | Roshchino | |
Russian Federation | Alkermes Investigational Site | Rostov-on-Don | |
Russian Federation | Alkermes Investigational Site | Saint Petersburg | |
Russian Federation | Alkermes Investigational Site | Samara | |
Russian Federation | Alkermes Investigational Site | Saratow | |
Russian Federation | Alkermes Investigational Site | Tonnel'nyy | |
Serbia | Alkermes Investigational Site | Belgrad | |
Serbia | Alkermes Investigational Site | Belgrade | |
Serbia | Alkermes Investigational Site | Kragujevac | |
Serbia | Alkermes Investigational Site | Novi Kneževac | |
Ukraine | Alkermes Investigational Site | Kharkiv | |
Ukraine | Alkermes Investigational Site | Kherson | |
Ukraine | Alkermes Investigational Site | Kyiv | |
Ukraine | Alkermes Investigational Site | Lviv | |
Ukraine | Alkermes Investigational Site | Poltava | |
Ukraine | Alkermes Investigational Site | Smila | |
Ukraine | Alkermes Investigational Site | Vinnytsia | |
United Kingdom | Alkermes Investigational Site | Headington | |
United States | Alkermes Investigational Site | Anaheim | California |
United States | Alkermes Investigational Site | Atlanta | Georgia |
United States | Alkermes Investigational Site | Atlanta | Georgia |
United States | Alkermes Investigational Site | Atlanta | Georgia |
United States | Alkermes Investigational Site | Augusta | Georgia |
United States | Alkermes Investigational Site | Austin | Texas |
United States | Alkermes Investigational Site | Bellevue | Washington |
United States | Alkermes Investigational Site | Berlin | New Jersey |
United States | Alkermes Investigational Site | Brooklyn | New York |
United States | Alkermes Investigational Site | Canton | Ohio |
United States | Alkermes Investigational Site | Cerritos | California |
United States | Alkermes Investigational Site | Chicago | Illinois |
United States | Alkermes Investigational Site | Chicago | Illinois |
United States | Alkermes Investigational Site | Cincinnati | Ohio |
United States | Alkermes Investigational Site | Culver City | California |
United States | Alkermes Investigational Site | Dayton | Ohio |
United States | Alkermes Investigational Site | Decatur | Georgia |
United States | Alkermes Investigational Site | DeSoto | Texas |
United States | Alkermes Investigational Site | Eugene | Oregon |
United States | Alkermes Investigational Site | Flowood | Mississippi |
United States | Alkermes Investigational Site | Fort Worth | Texas |
United States | Alkermes Investigational Site | Garden Grove | California |
United States | Alkermes Investigational Site | Glendale | California |
United States | Alkermes Investigational Site | Grand Rapids | Michigan |
United States | Alkermes Investigational Site | Houston | Texas |
United States | Alkermes Investigational Site | Kansas City | Missouri |
United States | Alkermes Investigational Site | Las Vegas | Nevada |
United States | Alkermes Investigational Site | Lauderhill | Florida |
United States | Alkermes Investigational Site | Little Rock | Arkansas |
United States | Alkermes Investigational Site | Long Beach | California |
United States | Alkermes Investigational Site | Marlton | New Jersey |
United States | Alkermes Investigational Site | North Miami | Florida |
United States | Alkermes Investigational Site | Oakland | California |
United States | Alkermes Investigational Site | Oceanside | California |
United States | Alkermes Investigational Site | Orange | California |
United States | Alkermes Investigational Site | Palo Alto | California |
United States | Alkermes Investigational Site | Pico Rivera | California |
United States | Alkermes Investigational Site | Redlands | California |
United States | Alkermes Investigational Site | Richardson | Texas |
United States | Alkermes Investigational Site | Rochester | New York |
United States | Alkermes Investigational Site | Rogers | Arkansas |
United States | Alkermes Investigational Site | Saint Louis | Missouri |
United States | Alkermes Investigational Site | Saint Louis | Missouri |
United States | Alkermes Investigational Site | Saint Louis | Missouri |
United States | Alkermes Investigational Site | Saint Louis | Missouri |
United States | Alkermes Investigational Site | San Diego | California |
United States | Alkermes Investigational Site | Temecula | California |
United States | Alkermes Investigational Site | Torrance | California |
United States | Alkermes Investigational Site | Winfield | Illinois |
Lead Sponsor | Collaborator |
---|---|
Alkermes, Inc. |
United States, Austria, Bulgaria, Ireland, Israel, Italy, Korea, Republic of, Poland, Puerto Rico, Russian Federation, Serbia, Ukraine, United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Change from baseline in body weight | Up to 48 months | ||
Other | Change from baseline in Clinical Global Impression-Severity (CGI-S) scale | Up to 48 months | ||
Primary | Safety will be measured by frequency of serious and non-serious adverse events | Up to 48 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05039489 -
A Study on the Brain Mechanism of cTBS in Improving Medication-resistant Auditory Hallucinations in Schizophrenia
|
N/A | |
Completed |
NCT05321602 -
Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder
|
Phase 1 | |
Completed |
NCT05111548 -
Brain Stimulation and Cognitive Training - Efficacy
|
N/A | |
Completed |
NCT04503954 -
Efficacy of Chronic Disease Self-management Program in People With Schizophrenia
|
N/A | |
Completed |
NCT02831231 -
Pilot Study Comparing Effects of Xanomeline Alone to Xanomeline Plus Trospium
|
Phase 1 | |
Completed |
NCT05517460 -
The Efficacy of Auricular Acupressure on Improving Constipation Among Residents in Community Rehabilitation Center
|
N/A | |
Completed |
NCT03652974 -
Disturbance of Plasma Cytokine Parameters in Clozapine-Resistant Treatment-Refractory Schizophrenia (CTRS) and Their Association With Combination Therapy
|
Phase 4 | |
Recruiting |
NCT04012684 -
rTMS on Mismatch Negativity of Schizophrenia
|
N/A | |
Recruiting |
NCT04481217 -
Cognitive Factors Mediating the Relationship Between Childhood Trauma and Auditory Hallucinations in Schizophrenia
|
N/A | |
Completed |
NCT00212784 -
Efficacy and Safety of Asenapine Using an Active Control in Subjects With Schizophrenia or Schizoaffective Disorder (25517)(P05935)
|
Phase 3 | |
Completed |
NCT04092686 -
A Clinical Trial That Will Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With Schizophrenia
|
Phase 3 | |
Completed |
NCT01914393 -
Pediatric Open-Label Extension Study
|
Phase 3 | |
Recruiting |
NCT03790345 -
Vitamin B6 and B12 in the Treatment of Movement Disorders Induced by Antipsychotics
|
Phase 2/Phase 3 | |
Recruiting |
NCT05956327 -
Insight Into Hippocampal Neuroplasticity in Schizophrenia by Investigating Molecular Pathways During Physical Training
|
N/A | |
Terminated |
NCT03209778 -
Involuntary Memories Investigation in Schizophrenia
|
N/A | |
Terminated |
NCT03261817 -
A Controlled Study With Remote Web-based Adapted Physical Activity (e-APA) in Psychotic Disorders
|
N/A | |
Completed |
NCT02905604 -
Magnetic Stimulation of the Brain in Schizophrenia or Depression
|
N/A | |
Recruiting |
NCT05542212 -
Intra-cortical Inhibition and Cognitive Deficits in Schizophrenia
|
N/A | |
Completed |
NCT04411979 -
Effects of 12 Weeks Walking on Cognitive Function in Schizophrenia
|
N/A | |
Terminated |
NCT03220438 -
TMS Enhancement of Visual Plasticity in Schizophrenia
|
N/A |